https://hdl.handle.net/10807/204 2026-07-14T05:07:35Z https://hdl.handle.net/10807/342576 Titolo: Come il digitale rafforza i legami con i negozi di quartiere Autori: Cecilia Manzo Abstract: La trasformazione digitale viene spesso associata ad automazione, piattaforme eintelligenza artifi ciale. È una narrazione che spiega solo in parte ciò che accadenell’artigianato urbano e nei negozi di quartiere, ovvero nell’economia diprossimità, dove il valore nasce dalla fi ducia, dalla riconoscibilità e dalla continuitàdelle relazioni sociali. L’economia di prossimità fa riferimento a un tessuto socioeconomico che si basa surelazioni sociali di vicinato, radicate nella dimensione di territoriale del quartiere.Le attività economiche funzionano come presidi, non semplici luoghi di acquisto,ma spazi in cui si generano relazioni sociali e appartenenza. https://24plus.ilsole24ore.com/art/come-digitale-rafforza-legami-i-negozi-quartiere-AIUGfX8C 2026-01-01T00:00:00Z https://hdl.handle.net/10807/341370 Titolo: Il senso della differenza sessuale Autori: Canzi elena; iafrate raffaella Abstract: Il senso della differenza sessuale 2024-01-01T00:00:00Z https://hdl.handle.net/10807/340156 Titolo: Muhammad Makhzangi’s ‘The Smell of the Sun’ Autori: Mila Fantinelli Abstract: This article reviews Muhammad Makhzangi’s The Smell of the Sun (Rā’iḥat al-Shams, 2025), reading it as a late, inward-looking work shaped by memory, affection, aging, and the fragile continuity of life. Unlike Makhzangi’s earlier writings, often marked by travel, observation, and a scientific gaze, this collection of brief narratives turns toward home, family, loss, and the intimate textures of remembrance. The article explores how love becomes a form of inheritance, how memory moves between personal tenderness and collective pain, and how animals, the sea, and the aging body become figures of time and transformation. Through its attention to paternal bonds, captivity, Arab landscapes of grief, and the recurring threshold between life and death, The Smell of the Sun emerges as a meditation on what remains: gestures, traces, warmth, and the quiet persistence of care beyond disappearance. 2025-01-01T00:00:00Z https://hdl.handle.net/10807/338218 Titolo: Nerandomilast in progressive pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-ILD trial Autori: Wijsenbeek, Marlies S.; Assassi, Shervin; Azuma, Arata; Cottin, Vincent; Hoffmann-Vold, Anna-Maria; Maher, Toby M.; Martinez, Fernando J.; Oldham, Justin M.; Richeldi, Luca; Valenzuela, Claudia; Gu, Hui; Ritter, Ivana; Stowasser, Susanne; Kreuter, Michael; null, null Abstract: Background: In the FIBRONEER-ILD trial in patients with progressive pulmonary fibrosis (PPF), nerandomilast 9 mg bid and 18 mg bid reduced the decline in forced vital capacity at week 52 compared with placebo (the primary endpoint). We assessed the effects of nerandomilast up to the final database lock. Methods: Time to first acute exacerbation of ILD, hospitalisation for respiratory cause, or death (key secondary endpoint) and other time-to-event endpoints were assessed. Results: 1176 patients, of whom 512 were taking background nintedanib, received nerandomilast or placebo. At final database lock, mean (sd) exposure to trial medication was 15.1 (5.7) months and mean (sd) observation period was 17.0 (4.1) months. Compared with placebo, the hazard ratio (95% CI) for the key secondary endpoint was 0.78 (0.61, 1.00) for nerandomilast 9 mg bid and 0.77 (0.60, 0.99) for nerandomilast 18 mg bid; hazard ratios were lower among patients not taking nintedanib (0.69 [0.49, 0.97] and 0.65 [0.46, 0.92], respectively) than among those taking background nintedanib (0.90 [0.63, 1.30] and 0.93 [0.65, 1.34], respectively). For death, the hazard ratio (95% CI) versus placebo was 0.51 (0.34, 0.78) for both nerandomilast doses. Adverse events led to discontinuation of trial medication in 12.5%, 12.0% and 12.3% of the placebo, nerandomilast 9 mg bid and nerandomilast 18 mg bid groups, respectively. Conclusions: In the FIBRONEER-ILD trial in patients with PPF, nerandomilast reduced the risk of clinically important outcomes, including death, over the whole trial. Nerandomilast had a favourable safety and tolerability profile. 2026-01-01T00:00:00Z